Published 02-04-19
Issued by Novartis
For the sixth consecutive year, Novartis is publishing an annual Novartis in Society report (formerly our Corporate Responsibility Report).
For the sixth consecutive year, Novartis is publishing an annual Novartis in Society report (formerly our Corporate Responsibility Report).
The report is divided into four chapters based on our corporate responsibility (CR) material clusters and the global health and CR strategic priorities: holding ourselves to the highest ethical standards; being part of the solution on pricing and access; addressing global health challenges; and being a responsible citizen. In each chapter, readers will find more focused and contextual information about the priority topics arising from our CR materiality assessment.
The report has been prepared in accordance with the GRI Standards: Core option. And it supplements the CR chapter in the 2018 Novartis Annual Review and the 2018 Novartis Annual Report.
In 2018, we were proud to be ranked #2 in the Access to Medicine Index, and to again be included in the Dow Jones Sustainability World Index (#4) and the DJSI Europe Index. Novartis was also included in several reputation and innovation rankings, including the Thomson Reuters Diversity & Inclusion Index (#2), the Nature Index (#3), the Pharmaceutical Innovation Index (#3) and PatientView’s reputation survey (#4). And we were recognized as one of the most sustainable corporations (#64) by Corporate Knights, one of the World's Most Innovative Companies (#1 in biotech and #21 overall) by Fast Company and one of the most admired pharmaceutical companies (#3) by Fortune.
2018 Highlights
Download the Novartis in Society 2018 report
Share your feedback.
For more information on our corporate responsibility activities, visit our website.
Novartis Media Relations
Central media line: +41 61 324 2200
E-mail: media.relations@novartis.com
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.